UroGen Pharma Ltd. (URGN)

NASDAQ: URGN · Real-Time Price · USD
13.10
+0.26 (2.02%)
At close: Sep 18, 2024, 4:00 PM
13.67
+0.57 (4.33%)
After-hours: Sep 18, 2024, 5:22 PM EDT
2.02%
Market Cap 551.69M
Revenue (ttm) 85.01M
Net Income (ttm) -113.58M
Shares Out 42.11M
EPS (ttm) -3.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,192,614
Open 13.00
Previous Close 12.84
Day's Range 12.75 - 13.41
52-Week Range 10.60 - 20.70
Beta 1.12
Analysts Strong Buy
Price Target 48.38 (+269.31%)
Earnings Date Nov 12, 2024

About URGN

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company’s lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate ris... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 4, 2017
Employees 201
Stock Exchange NASDAQ
Ticker Symbol URGN
Full Company Profile

Financial Performance

In 2023, UroGen Pharma's revenue was $82.71 million, an increase of 28.52% compared to the previous year's $64.36 million. Losses were -$102.24 million, -6.87% less than in 2022.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for URGN stock is "Strong Buy." The 12-month stock price forecast is $48.38, which is an increase of 269.31% from the latest price.

Price Target
$48.38
(269.31% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Announces Patent Allowance.

2 days ago - Business Wire

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

13 days ago - Business Wire

UroGen Pharma's JELMYTO And UGN-102: A Strong Buy In The Urological Cancer Sector

UroGen Pharma stock is a strong buy due to its innovative RTGel technology and promising pipeline, including JELMYTO and UGN-102, targeting urological cancers. URGN's JELMYTO shows impressive clinical...

20 days ago - Seeking Alpha

UroGen Pharma to Present at Upcoming Investor Conferences

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

20 days ago - Business Wire

UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a leading biotech company specializing in novel therapies for urothelial and specialty cancers, today announced the successful comp...

5 weeks ago - Business Wire

UroGen Pharma Ltd. (URGN) Q2 2024 Earnings Call Transcript

UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2024 Earnings Call August 13, 2024 10:00 AM ET Company Participants Vincent Perrone - Head, Investor Relations Liz Barrett - President and Chief Executive Officer ...

5 weeks ago - Seeking Alpha

UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

5 weeks ago - Business Wire

UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

6 weeks ago - Business Wire

UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

3 months ago - Business Wire

UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

PRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and speci...

3 months ago - GlobeNewsWire

UroGen: Q3 NDA Opens Hefty Revenue Opportunity

ENVISION DOR data released in Q2, 2024 showed an unprecedented 82.3% Duration of Response for UGN-102. Following such positive data, it expects to make an FDA submission late in Q3, 2024, with potenti...

3 months ago - Seeking Alpha

Uber Advertising Announces Exclusive Partnership with T-Mobile Advertising Solutions

SAN FRANCISCO & BELLEVUE, Wash.--(BUSINESS WIRE)--Today, Uber's advertising division announced an exclusive partnership with T-Mobile Advertising Solutions and its rideshare media network – Octopus In...

Other symbols: GDYN
3 months ago - Business Wire

AscellaHealth Chairman and President Bill Oldham Named 2024 Philadelphia Titan 100

BERWYN, Pa.--(BUSINESS WIRE)--Bill Oldham, chairman and president, AscellaHealth, honored as a 2024 Philadelphia Titan 100.

3 months ago - Business Wire

UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today an...

3 months ago - Business Wire

UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today sh...

3 months ago - Business Wire

UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

3 months ago - Business Wire

UroGen Pharma Appoints David Lin as New Chief Commercial Officer

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today an...

3 months ago - Business Wire

UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

4 months ago - Business Wire

UroGen Pharma Ltd. (URGN) Q1 2024 Earnings Call Transcript

UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2024 Earnings Conference Call May 13, 2024 10:00 AM ET Company Participants Vincent Perrone - Head of IR Elizabeth Barrett - President & CEO Mark Schoenberg - Chie...

4 months ago - Seeking Alpha

UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

4 months ago - Business Wire

UroGen Pharma to Participate at Upcoming Investor Conferences

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

4 months ago - Business Wire

New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today hi...

4 months ago - Business Wire

UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024

PRINCETON, N.J--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, toda...

4 months ago - Business Wire

New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today hi...

4 months ago - Business Wire

UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

4 months ago - Business Wire